Rigel Pharmaceuticals price target raised to $1.75 from $1.25 at B. Riley

B. Riley raised the firm’s price target on Rigel Pharmaceuticals to $1.75 from $1.25 and keeps a Neutral rating on the shares after the company added Gavreto to its portfolio. The firm views the transaction as net present value positive and says Gavreto has the potential to capture additional market share from its competitor, the analyst tells investors in a research note.